首页> 外文期刊>Journal of drug targeting >Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses.
【24h】

Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses.

机译:可生物降解的纳米粒子介导的抗原递送至人脐带血来源的树突状细胞,以诱导原代T细胞反应。

获取原文
获取原文并翻译 | 示例
           

摘要

Dendritic cells (DCs) in the peripheral tissues act as sentinels of the immune system. They detect and capture pathogens entering the body and present their antigens to T cells to trigger responses directed towards elimination of the pathogen. The induction of peripheral tolerance against self and certain foreign antigens is also believed to be mediated through DCs. The outcome of any immune response is largely controlled by the microenvironment of antigen capture, processing and presentation by DCs. The "context" of antigen delivery to DCs will directly influence the microenvironment of antigen presentation and hence the regulation of immune responses. We report here preliminary investigations describing the formulation of a pharmaceutically acceptable, biodegradable, and strategic nanoparticulate delivery system, and its application for efficient antigen loading of DCs to achieve antigen specific T cell activation. Pathogen-mimicking fabricated by incorporating monophosphoryl lipid A (MPLA; toll-likereceptor (TLR) 4 ligand) or CpG ODN (seq #2006; TLR9 ligand) in biodegradable copolymer, poly(D,L,-lactic-co-glycolic acid) (PLGA). The uptake of PLGA nanoparticles by human umbilical cord blood derived DCs (DCs propagated from CD34 progenitors) was conclusively demonstrated by scanning electron microscopy (SEM), fluorescence activated cell sorting (FACS) and confocal laser scanning microscopy (CLSM). Cell phenotype at day 12 of cultures was determined as immature DC using specific cell surface markers, i.e. CD11c (approximately 90%), MHC-II (approximately 70%), CD86 (approximately 20%), CD83 (approximately 5%), CD80 (approximately 40%), CD40 (approximately 40%), and CCR7 (approximately 5%). Tetanus toxoid (TT), a model antigen, was encapsulated in nanoparticles along with an immunomodulator, i.e. either MPLA or CpG ODN. DCs pulsed with various antigen formulations were co-cultured with autologous naive T cells at various cell ratios (DC: T cells were 1:5-20). The DCs pulsed with TT and MPLA together in nanoparticles induced significantly higher T cell proliferation (P<0.05) as compared to when DCs pulsed with TT and MPLA in solution were employed. A similar trend was observed when CpG ODN was used instead of MPLA in the TT nanoparticles. This strategy of antigen delivery to DCs was then tested with a cancer vaccine candidate, a MUC1 lipopeptide. The T cell proliferation observed in the presence of nanoparticulate MUC1 and MPLA pulsed-DCs was much higher than DCs pulsed with soluble antigen (P<0.0005). These results indicate that PLGA nanoparticles mimicking certain features of pathogens are efficient delivery systems for targeting vaccine antigens to DCs and activation of potent T cell responses.
机译:外周组织中的树突状细胞(DC)充当免疫系统的前哨。他们检测并捕获进入人体的病原体,并将其抗原呈递给T细胞,以触发针对消除病原体的反应。还认为诱导针对自身和某些外来抗原的外周耐受性是通过DC介导的。任何免疫应答的结果在很大程度上受DC捕获,加工和呈递抗原的微环境控制。抗原递送至DC的“背景”将直接影响抗原呈递的微环境,并因此影响免疫应答的调节。我们在这里报告初步调查,描述可药用的,可生物降解的和战略性的纳米颗粒递送系统的配方,及其对DC的有效抗原加载以实现抗原特异性T细胞活化的应用。通过将单磷酰脂质A(MPLA; Toll样受体(TLR)4配体)或CpG ODN(seq#2006; TLR9配体)掺入可生物降解的共聚物聚(D,L,-乳酸-乙醇酸共聚物)中来模拟病原体(PLGA)。通过扫描电子显微镜(SEM),荧光激活细胞分选(FACS)和共聚焦激光扫描显微镜(CLSM)最终证明了人脐带血来源的DC(从CD34祖细胞传播的DC)对PLGA纳米颗粒的摄取。使用特定的细胞表面标记,即CD11c(约90%),MHC-II(约70%),CD86(约20%),CD83(约5%),CD80,将培养第12天的细胞表型确定为未成熟DC。 (大约40%),CD40(大约40%)和CCR7(大约5%)。破伤风类毒素(TT)(一种模型抗原)与免疫调节剂(即MPLA或CpG ODN)一起封装在纳米颗粒中。将以各种抗原制剂脉冲的DC与自体幼稚T细胞以各种细胞比例(DC:T细胞为1:5-20)共培养。与在溶液中使用TT和MPLA脉冲的DC相比,在纳米颗粒中用TT和MPLA脉冲一起的DC诱导了显着更高的T细胞增殖(P <0.05)。当在TT纳米颗粒中使用CpG ODN代替MPLA时,观察到类似的趋势。然后用癌症疫苗候选物MUC1脂肽测试了这种将抗原递送至DC的策略。在纳米颗粒MUC1和MPLA脉冲DC的存在下观察到的T细胞增殖远高于用可溶性抗原脉冲的DC(P <0.0005)。这些结果表明,模仿病原体某些特征的PLGA纳米颗粒是将疫苗抗原靶向DC并激活有效T细胞反应的有效递送系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号